Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 6/20 | 0.58 |
| ▸ | PLAU | P00749 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829835 | 0.87 | SLC9A1 (0.63) | SLC9A1PLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL29513087 | 0.85 | SLC9A1 (0.63) | SLC9A1PLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL15697558 | 0.85 | SLC9A1 (0.63) | SLC9A1PLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL9612657 | 0.84 | SLC9A1 (0.56) | SLC9A1PLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL5584284 | 0.84 | HDAC3 (0.52) | SLC9A1PLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL721446 | 0.84 | L3MBTL1 (0.57) | SLC9A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15698911 | 0.84 | HDAC3 (0.52) | SLC9A1PLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL8329863 | 0.83 | HDAC3 (0.51) | SLC9A1PLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL828439 | 0.83 | HDAC3 (0.68) | SLC9A1PLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL29749510 | 0.83 | ALDH1A1 (0.51) | SLC9A1PLAUHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9894901-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-20 | — | — | US | disclosed |
| US-9894901-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-20 | — | — | US | disclosed |
| US-9894901-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-20 | — | — | US | disclosed |
| EP-2616460-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMA CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2013-10-03 | — | — | US | disclosed |
| WO-2013137479-A1 | DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-09-19 | — | — | WO | disclosed |
| US-8143307-B2 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-03-27 | — | — | US | disclosed |
| WO-2012036253-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
| US-20100004466-A1 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-01-07 | — | — | US | disclosed |
| EP-1831192-A4 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RES INST CHEM TECH (KR) | 2009-08-19 | — | — | EP | disclosed |
| EP-1831192-A1 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Korea Research Institute of Chemical Technology (KR) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006071047-A1 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-06 | — | — | WO | disclosed |
| US-5340833-A | Antiarthritic, antiinflammatory, antitumor agents | EISAI CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0568289-A2 | Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors | Eisai Co., Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | SLC9A1 1342/4885PLAU 4532/4885HDAC3 117/4885 |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | FGF2, BROX, BOLA2; BOLA2B | SLC9A1 1138/4885PLAU 4709/4885HDAC3 1609/4885 |
| US-20100004466-A1 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | TNNI3, TNNT2, SLC9A2 | SLC9A1 5/4885PLAU 2876/4885HDAC3 1223/4885 |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | SLC9A1 394/4885PLAU 3960/4885HDAC3 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.